Modulation of cxcr4 and related methods and compositions

Abstract

A method for inhibiting the SDF1-CXCR4 signaling pathway in a subject, comprising administering to the subject an effective amount of a Beta Defensin (BD)-inducing agent. The BD-inducing agent may be a Fusobacterium associated defensin inducer (FAD-I) polypeptide or a double stranded RNA analog.

1 . A method for inhibiting the SDF1-CXCR4 signaling pathway in a subject, comprising administering to the subject an effective amount of a BD-inducing agent.  
     
     
         2 . The method of  claim 1 , wherein the BD-inducing agent is a  Fusobacterium  associated defensin inducer (FAD-I) polypeptide.  
     
     
         3 . The method of  claim 1 , wherein the BD-inducing agent is a synthetic analog of double stranded RNA.  
     
     
         4 . The method of  claim 3 , wherein the BD-inducing agent is polyinosine-polycytidylic acid  
     
     
         5 . The method of  claim 1 , wherein the selected agent is administered systemically.  
     
     
         6 . The method of  claim 1 , wherein the agent is administered locally.  
     
     
         7 . The method of  claim 2 , wherein the FAD-I polypeptide comprises an amino acid sequence at least 90 percent identical to an amino acid sequence selected from the group consisting of SEQ. ID. NOs.: 1, 3, 5, and 7.  
     
     
         8 . The method of  claim 7 , wherein the FAD-I polypeptide comprises an amino acid sequence at least 95 percent identical to an amino acid sequence selected from the group consisting of SEQ. ID. NOs.: 1, 3, 5, and 7.  
     
     
         9 . The method of  claim 2 , wherein the FAD-I polypeptide in encoded by a nucleic acid comprising a sequence at least 90 percent identical to a nucleic acid sequence selected from the group consisting of SEQ. ID. NOs.: 2, 4, 6, and 8.  
     
     
         10 . The method of  claim 9 , wherein the FAD-I polypeptide in encoded by a nucleic acid comprising a sequence at least 95 percent identical to a nucleic acid sequence selected from the group consisting of SEQ. ID. NOs.: 2, 4, 6, and 8.  
     
     
         11 . The method of  claim 1 , wherein the method inhibits a CXCR4-related process in a subject.  
     
     
         12 . The method of  claim 1 , wherein the method stimulates the mobilization of hematopoietic stem cells in the subject.  
     
     
         13 . The method of  claim 1 , wherein the method inhibits angiogenesis in a subject.  
     
     
         14 . The method of  claim 12 , wherein the angiogenesis is tumor angiogenesis.  
     
     
         15 . The method of  claim 1 , wherein the method stimulates an immune response in the subject.  
     
     
         16 . The method of  claim 15 , wherein the agent is administered systemically.  
     
     
         17 . The method of  claim 15 , wherein the agent is administered locally.  
     
     
         18 . The method of  claim 1 , wherein the method promotes cardiogenesis in the subject.  
     
     
         19 . The method of  claim 1 , wherein the agent is administered systemically.  
     
     
         20 . The method of  claim 15 , wherein the agent is administered locally.